Shaily Engineering Plastics (501423) Q1 25/26 earnings summary

Executive summary

• Q1 FY26 revenue grew 38% year-over-year to INR 246.7 crores, driven by a 181% surge in healthcare segment revenue and capacity expansion initiatives.

• EBITDA margin expanded by 840 basis points to 28.5%, with EBITDA at INR 70.4 crores (95% growth).

• PAT rose 146% year-over-year to INR 41.1 crores, with PAT margin at 16.7%.

• Major capacity expansions underway, targeting 70–75 million pen capacity by early FY27, with INR 125 crore CapEx planned.

• Unaudited standalone and consolidated financial results for Q1 FY26 were reviewed and approved by the Board on August 11, 2025.

Financial highlights

• Q1 FY26 consolidated revenue: INR 246.7 crores, up from INR 179.4 crores in Q1 FY25 (38% growth).

• EBITDA nearly doubled to INR 70.4 crores, margin at 28.5%.

• PAT increased to INR 41.1 crores (146% growth), PAT margin at 16.7%.

• Cash PAT at INR 52.6 crores, up 91% year-over-year.

• Standalone EPS for Q1 FY26 was INR 7.83 (basic), up from INR 2.13 year-over-year.

Outlook and guidance

• Healthcare business expected to drive significant revenue and profitability growth over the next few years.

• 19 new injection molding machines being installed to meet healthcare demand, completion expected by Q2 FY26.

• Capacity expansions aligned with anticipated customer demand and volume commitments for the next 3–5 years.

• Guidance remains on track, with higher pharma revenues projected in Q3 and Q4.